Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 5/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177568 | 1.00 | CA2 (0.60) | CA2CA4CASP3EPHX2CYP2C9 | |
| SCHEMBL15605900 | 1.00 | CA2 (0.60) | CA2CA4CASP3EPHX2CYP2C9 | |
| SCHEMBL10020471 | 0.96 | CA2 (0.56) | CA2CA4CASP3EPHX2CYP2C9 | |
| SCHEMBL10076119 | 0.85 | ECE1 (0.53) | CA2CA4CYP2C9MMEPIN1 | |
| SCHEMBL14088908 | 0.85 | CA2 (0.55) | CA2CA4CASP3EPHX2MME | |
| SCHEMBL12426671 | 0.85 | CA2 (0.55) | CA2CA4CASP3EPHX2MME | |
| SCHEMBL4182303 | 0.85 | ECE1 (0.53) | CA2CA4CYP2C9MMEPIN1 | |
| SCHEMBL4182306 | 0.85 | ECE1 (0.53) | CA2CA4CYP2C9MMEPIN1 | |
| SCHEMBL17624828 | 0.84 | CA2 (0.44) | CA2CA4CASP3EPHX2CYP2C9 | |
| SCHEMBL17636441 | 0.84 | CA2 (0.44) | CA2CA4CASP3EPHX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186853-A1 | COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J | 2009-07-23 | — | — | US | claimed |
| EP-1865953-A4 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J (US) | 2008-04-30 | — | — | EP | claimed |
| EP-1865953-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | Yu, Ruey J., Dr. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006101940-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU, RUEY, J. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060211754-A1 | Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof | YU RUEY J | 2006-09-21 | — | — | US | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | claimed |
| US-20130157298-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYCLICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2206736-A1 | Polyglutamate-amino acid conjugates and methods | Nitto Denko Corporation (JP) | 2010-07-14 | — | — | EP | disclosed |
| CN-101492494-A | Integrin ligand cyclic peptide analogues and cyclization method | UNIV ZHEJIANG (CN) | 2009-07-29 | — | — | CN | disclosed |
| US-20090186853-A1 | COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J | 2009-07-23 | — | — | US | disclosed |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYLICS, INC. A DELAWARE CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1865953-A4 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1865953-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | Yu, Ruey J., Dr. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006101940-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU, RUEY, J. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060211754-A1 | Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof | YU RUEY J | 2006-09-21 | — | — | US | disclosed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005055947-A2 | ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS | YU RUEY J (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-0015544-B1 | DERIVATIVES OF THE MERCAPTOPROPIONAMIDO-ACETIC ACID, PROCESS FOR THE PREPARATION THEREOF AND COMPOSITIONS | ZAMBON S.p.A. (IT) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | F13B, HABP2, F7 | CA2 2419/4885CA4 1577/4885CASP3 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.